1-11 of 11
Martin A. Cheever
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A phase II open label, randomized clinical trial of atezolizumab with or without human recombinant IL-7 (CYT107) in advanced urothelial cancer

Randy F. Sweis, Gurkamal S. Chatta, Rohit K. Jain, Helen Moon, Scott Edward. Delacroix, Alana Fang, Leonard D’Amico, Angela Shaulov. Kask, Martin A. Cheever, Steven Fling, Elad Sharon, Andreanne Lacroix, Judith C. Kaiser, Russell K. Pachynski, Evan Y. Yu
Journal: Clinical Cancer Research
Clin Cancer Res (2024)
https://doi.org/10.1158/1078-0432.CCR-24-1728
Published: 22 November 2024
View article titled, A phase II open label, randomized clinical trial of atezolizumab with or without human recombinant IL-7 (CYT107) in advanced urothelial cancer
Open the PDF for A phase II open label, randomized clinical trial of atezolizumab with or without human recombinant IL-7 (CYT107) in advanced urothelial cancer in another window
Includes: Supplementary data
Journal Articles

Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Katelyn T. Byrne, Courtney B. Betts, Rosemarie Mick, Shamilene Sivagnanam, David L. Bajor, Daniel A. Laheru, E. Gabriela Chiorean, Mark H. O'Hara, Shannon M. Liudahl, Craig Newcomb, Cécile Alanio, Ana P. Ferreira, Byung S. Park, Takuya Ohtani, Austin P. Huffman, Sara A. Väyrynen, Andressa Dias Costa, Judith C. Kaiser, Andreanne M. Lacroix, Colleen Redlinger, Martin Stern, Jonathan A. Nowak, E. John Wherry, Martin A. Cheever, Brian M. Wolpin, Emma E. Furth, Elizabeth M. Jaffee, Lisa M. Coussens, Robert H. Vonderheide
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4574–4586.
https://doi.org/10.1158/1078-0432.CCR-21-1047
Published: 15 August 2021
View article titled, Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer
Open the PDF for Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors

Kim Margolin, Chihiro Morishima, Vamsidhar Velcheti, Jeffrey S. Miller, Sylvia M. Lee, Ann W. Silk, Shernan G. Holtan, Andreanne M. Lacroix, Steven P. Fling, Judith C. Kaiser, Jack O. Egan, Monica Jones, Peter R. Rhode, Amy D. Rock, Martin A. Cheever, Hing C. Wong, Marc S. Ernstoff
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (22): 5552–5561.
https://doi.org/10.1158/1078-0432.CCR-18-0945
Published: 15 November 2018
View article titled, Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors

Jeffrey S. Miller, Chihiro Morishima, Douglas G. McNeel, Manish R. Patel, Holbrook E.K. Kohrt, John A. Thompson, Paul M. Sondel, Heather A. Wakelee, Mary L. Disis, Judith C. Kaiser, Martin A. Cheever, Howard Streicher, Steven P. Creekmore, Thomas A. Waldmann, Kevin C. Conlon
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (7): 1525–1535.
https://doi.org/10.1158/1078-0432.CCR-17-2451
Published: 02 April 2018
View article titled, A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors
Open the PDF for A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors in another window
Journal Articles

PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine

Martin A. Cheever, Celestia S. Higano
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (11): 3520–3526.
https://doi.org/10.1158/1078-0432.CCR-10-3126
Published: 01 June 2011
View article titled, PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
Open the PDF for PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine in another window
Journal Articles

The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

Martin A. Cheever, James P. Allison, Andrea S. Ferris, Olivera J. Finn, Benjamin M. Hastings, Toby T. Hecht, Ira Mellman, Sheila A. Prindiville, Jaye L. Viner, Louis M. Weiner, Lynn M. Matrisian
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (17): 5323–5337.
https://doi.org/10.1158/1078-0432.CCR-09-0737
Published: 31 August 2009
View article titled, The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
Open the PDF for The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research in another window
Includes: Supplementary data
Journal Articles

Translational Research Working Group Developmental Pathway for Immune Response Modifiers

Martin A. Cheever, Jeffrey Schlom, Louis M. Weiner, H. Kim Lyerly, Mary L. Disis, Addison Greenwood, Oren Grad, William G. Nelson, for the Translational Research Working Group
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (18): 5692–5699.
https://doi.org/10.1158/1078-0432.CCR-08-1266
Published: 14 September 2008
View article titled, Translational Research Working Group Developmental Pathway for Immune Response Modifiers
Open the PDF for Translational Research Working Group Developmental Pathway for Immune Response Modifiers in another window
Journal Articles

Toxicity, Immunogenicity, and Induction of E75-specific Tumor-lytic CTLs by HER-2 Peptide E75 (369–377) Combined with Granulocyte Macrophage Colony-stimulating Factor in HLA-A2+ Patients with Metastatic Breast and Ovarian Cancer

James L. Murray, Michael E. Gillogly, Donna Przepiorka, Hannah Brewer, Nuhad K. Ibrahim, Daniel J. Booser, Gabriel N. Hortobagyi, Andrzej P. Kudelka, Kenneth H. Grabstein, Martin A. Cheever, Constantin G. Ioannides
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (11): 3407–3418.
Published: 01 November 2002
View article titled, Toxicity, Immunogenicity, and Induction of E75-specific Tumor-lytic CTLs by HER-2 Peptide E75 (369–377) Combined with Granulocyte Macrophage Colony-stimulating Factor in HLA-A2+ Patients with Metastatic Breast and Ovarian Cancer
Open the PDF for Toxicity, Immunogenicity, and Induction of E75-specific Tumor-lytic CTLs by HER-2 Peptide E75 (369–377) Combined with Granulocyte Macrophage Colony-stimulating Factor in HLA-A2+ Patients with Metastatic Breast and Ovarian Cancer in another window
Journal Articles

Immunization of Cancer Patients with a HER-2/neu, HLA-A2 Peptide, p369–377, Results in Short-lived Peptide-specific Immunity

Keith L. Knutson, Kathy Schiffman, Martin A. Cheever, Mary L. Disis
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (5): 1014–1018.
Published: 01 May 2002
View article titled, Immunization of Cancer Patients with a HER-2/neu, HLA-A2 Peptide, p369–377, Results in Short-lived Peptide-specific Immunity
Open the PDF for Immunization of Cancer Patients with a HER-2/neu, HLA-A2 Peptide, p369–377, Results in Short-lived Peptide-specific Immunity in another window
Journal Articles

WT1-specific Serum Antibodies in Patients with Leukemia

Alexander Gaiger, Lauren Carter, Hildegard Greinix, Darrick Carter, Patricia D. McNeill, Raymond L. Houghton, Charisa D. Cornellison, Thomas S. Vedvick, Yasir A. W. Skeiky, Martin A. Cheever
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (3): 761s–765s.
Published: 01 March 2001
View article titled, WT1-specific Serum Antibodies in Patients with Leukemia
Open the PDF for WT1-specific Serum Antibodies in Patients with Leukemia in another window
Journal Articles

Generation of Immunity to the HER-2/neu Oncogenic Protein in Patients with Breast and Ovarian Cancer Using a Peptide-based Vaccine

Mary L. Disis, Kenneth H. Grabstein, Paul R. Sleath, Martin A. Cheever
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (6): 1289–1297.
Published: 01 June 1999
View article titled, Generation of Immunity to the HER-2/<em>neu</em> Oncogenic Protein in Patients with Breast and Ovarian Cancer Using a Peptide-based Vaccine
Open the PDF for Generation of Immunity to the HER-2/<em>neu</em> Oncogenic Protein in Patients with Breast and Ovarian Cancer Using a Peptide-based Vaccine in another window